This page is for clinic owners and marketing teams who produce website content, social media posts, or paid ads targeting Dutch patients. It tells you which phrases and mechanics get clinics reported, what you can write instead, and where the unique Dutch rules — like the mandatory safety warning — catch foreign clinics by surprise.
Who This Page Is For
If your clinic is based in the Netherlands — or if you are outside the Netherlands and running Dutch-language ads, social posts, or landing pages targeting Dutch patients — this guide applies to you. The rules catch foreign clinics just as readily as local ones.
The Dutch market feels more liberal than Germany, and in some ways it is. There is no single blanket advertising prohibition like Germany’s HWG. But that apparent openness masks something more dangerous: your campaign can pass a standard “advertising law” review and still be reported by five separate authorities for consumer law, privacy law, healthcare quality, professional discipline, and unfair commercial practices — all at once. That multi-front exposure is what makes the Netherlands distinctively risky.
The Netherlands runs healthcare advertising through a layered stack rather than one dominant statute. The core transparency law (Wmg) requires clinics to give patients clear tariff information and prohibits misleading statements in any content about services. On top of that, civil law prohibits unfair commercial practices including misleading omissions. The patient consent framework means that marketing copy that overpromises results — then leaves the real risk discussion to the consultation — creates liability on two separate tracks: advertising law and care law. This double-exposure is not theoretical; Dutch enforcement bodies cite it explicitly.
The three violation patterns that dominate Dutch enforcement are: discount and urgency mechanics applied to medical cosmetic treatments (explicitly prohibited, confirmed by multiple rulings including as recently as January 2026), price-first advertising that treats a Botox package like a gym membership promotion, and promotion of prescription-medicine injectables without the required physician traceability and mandatory safety warning. Foreign clinics running Dutch-language social campaigns routinely miss the mandatory safety warning text — a hard legal requirement that has no equivalent in Austria, Germany, or Switzerland.
The Dutch Trigger Word List
These are the phrases most frequently flagged in Dutch compliance reviews. Swap them out before anything else.
| What you wrote | Why it’s a problem | What to write instead |
|---|---|---|
| Gegarandeerd resultaat | Outcome guarantees are prohibited under Wmg and the Dutch Advertising Code. No treatment result can be guaranteed; the claim is both misleading and inconsistent with the pre-treatment information patients are legally owed. | Resultaten variëren — bespreken we tijdens het consult |
| Risicovri / pijnloos (als belofte) | Claims that a procedure is risk-free or pain-free are classic misleading efficacy claims. Even minimally invasive procedures carry risk; Dutch consumer law and the advertising code both prohibit this framing. | Schonend en nauwkeurig uitgevoerd — risico’s bespreken we persoonlijk |
| Speciale aanbieding — nog X dagen geldig | Time-limited discounts on medical cosmetic treatments create unlawful urgency pressure. Confirmed violation: RCC 2019/00470 (M1 Med Beauty, Instagram, 20% korting op injectables). This applies to all physician-performed aesthetic treatments. | Vaste tarieven — overzicht op onze website |
| Stackelkorting / pakketkorting (as main message) | Even permanent package pricing violates Dutch rules if the ad is price-first with no substantive medical information. Confirmed: RCC 2025/00608 (Fairday Clinics, Jan 2026). The test is not “is it temporary?” but “is price the sole sales argument?” | Behandelkosten bespreken we tijdens het eerste gesprek — kwaliteit en veiligheid staan voorop |
| Beste kliniek van Amsterdam / Nederland | Unverifiable superiority claims violate Dutch unfair commercial practices law. Without a documented, third-party verified basis, these claims mislead and are actionable by the ACM. | Erkend door [verified third party] / Aangesloten bij [verified body] |
| Botox-aanbieding / Botox-deal | Botox is a prescription product. Public advertising for prescription medicines is prohibited under Dutch law and enforced by the IGJ — online and offline. The word “aanbieding” (offer) adds a discount mechanic that compounds the violation. | Botulinum-toxinebehandeling — fachärztlich beoordeeld — raadpleeg uw arts |
| Patiënte zegt: “Mijn resultaat is geweldig!” | Patient testimonials used as promotional drivers must be clearly identifiable as advertising if there is a commercial relationship. In a medical cosmetic context, the CCBA prohibits using patient recommendations as a selling point. | Informatie over behandelingen en wat u kunt verwachten: [link to educational page] |
| Specialist in esthetische geneeskunde (zonder BIG-specialisme) | Claiming a specialism without a corresponding BIG-registered specialist title is a misleading statement about professional qualifications. It falls under both unfair commercial practices law and professional discipline rules for BIG-registered doctors. | Arts met focus op esthetische behandelingen, BIG-geregistreerd [BIG-nummer] |
| Vóór/na foto’s bekijken | Using before/after imagery for promotional purposes requires specific written GDPR-compliant consent for marketing publication — separate from treatment consent. In a prescription-product context (Botox/fillers), such imagery may also constitute unlawful medicine advertising. | Meer informatie over de behandeling en wat u realistisch kunt verwachten: [link] |
| Geen wachtlijsten — direct behandeld | Urgency implied by availability framing can tip into time-pressure territory in the medical cosmetic context. It also risks creating a WGBO problem: patients need adequate time to consider treatment information before consenting. Rushing that window is a care-law issue, not just an advertising issue. | Wij streven naar korte wachttijden — vraag naar beschikbaarheid |
5 Real-World Rewrites — Before & After
Each example uses real Dutch marketing copy patterns. The rewrites are designed to read like actual clinic content — not legal disclaimers.
Problems: outcome guarantee (“pijnloos”) is a prohibited efficacy claim; unverified superlative (“beste kliniek van Amsterdam”) violates unfair commercial practices law; “1.200 tevreden patiënten” is an unsubstantiated promotional statistic.
Why it’s lower risk: no outcome guarantee, no unverifiable superlative, pricing deferred to consultation, BIG registration referenced. Aligns with Wmg tariff information duty and WGBO pre-treatment information obligation.
Problems: outcome guarantee prohibited; before/after images require separate GDPR-compliant marketing consent; urgency mechanic (“nog 5 plekken”) creates unlawful time pressure for a non-necessary surgical procedure; price as lead message with urgency compounds the CCBA violation.
Why it’s lower risk: realistic framing, no before/after, no urgency, pricing deferred. The consultation framing also maps to the WGBO requirement that risks and alternatives are discussed before treatment decision.
Problems: “Botox” as a prescription product cannot be publicly advertised with promotional mechanics; time-limited discount = CCBA violation (RCC 2019/00470); “risicovri” is a prohibited risk-free claim; before/after Instagram content = unlawful medicine advertising on social media per IGJ guidance; mandatory CCBA warning text absent entirely.
Why it’s lower risk: uses the generic product name (not the brand), removes all promotional mechanics, names the BIG-registered physician, and includes the mandatory CCBA warning text. This is the minimum viable ad for any injectable treatment in the Netherlands.
Problems: “Revolutionaire” is an inflated product claim; patient quote used as promotional driver in a commercial context violates CCBA; “eerste behandeling gratis” deadline = unlawful time pressure; the combination creates a CCBA + BW unfair commercial practices triple violation.
Why it’s lower risk: no testimonial, no inflated product claim, no urgency mechanic, individual results framing. Keeps the promotional logic limited to what the treatment actually delivers after proper consultation.
Problems: no commercial relationship disclosure violates RSM (Dutch Social Media Code) and BW 6:193g; prescription product (Botox) publicly promoted by influencer — IGJ confirmed this applies to third parties and social media; before/after content in injectable context = unlawful medicine advertising; promotional discount code = price pressure in a medical context; mandatory CCBA warning absent; the clinic is co-responsible for content it facilitates.
Why it’s lower risk: commercial relationship disclosed (#Advertentie at the start), no prescription product named, no before/after, no discount code, mandatory CCBA warning included. The clinic should brief influencer partners explicitly and retain evidence that the brief was given — the clinic bears co-responsibility for what the influencer publishes.
High-Risk Content — What Dutch Enforcement Has Actually Acted On
These are not interpretation calls — each is a confirmed violation or an explicit statutory prohibition with documented enforcement.
The risk: Any time-limited offer, opening discount, countdown timer, or urgency framing applied to physician-performed aesthetic treatments creates unlawful pressure under the Dutch medical cosmetic advertising code (CCBA Art. 2). This was explicitly confirmed in 2019 (M1 Med Beauty Instagram case) and remains active enforcement precedent.
In practice: “20% korting op alle injectables — alleen deze maand,” “opening aanbieding — Botox voor €149,” countdown timers next to treatment pricing, “nog X plekken beschikbaar” framing.
The risk: Permanent package pricing is not automatically safe. The January 2026 Fairday Clinics ruling confirmed that even a non-temporary “stacking discount” structure violates the CCBA if the ad is overwhelmingly price-focused and provides no substantive information about the nature, operation, or risks of the treatment. The test is not “is it temporary?” — it is “does price dominate over medical information?”
In practice: Botox package deals (“3 zones voor €299”), filler pricing tables with no clinical context, social ads that lead with price and add a generic disclaimer in small print.
The risk: Public advertising of prescription-only medicines is prohibited. This applies to clinics promoting injectable treatments (Botox, dermal fillers containing prescription substances), influencers promoting those treatments, and third-party publishers or affiliate partners who place the content. The IGJ enforces this online and on social media, and has confirmed that third-party publishers are co-responsible. IGJ fines are now published publicly from January 2026.
In practice: Social posts promoting “Botox” by name with efficacy claims, sponsored content featuring injectable results, discount codes for prescription injectable treatments placed via influencer channels.
The risk: All advertising for physician-performed medical cosmetic treatments must include the mandatory Dutch warning text: “Kijk uit. Jezelf mooier maken kan lelijk uitpakken. Een geslaagde ingreep begint bij een geschikte arts.” There is no equivalent requirement in Germany, Austria, or Switzerland. Foreign clinics targeting the Dutch market consistently miss this — it is a straightforward CCBA violation.
In practice: Any social post, website page, or landing page promoting Botox, fillers, rhinoplasty, blepharoplasty, or other physician-performed cosmetic procedures that omits this exact warning text.
The risk: Any ad for injectable procedures (Botox, fillers, mesotherapy) must be traceable to a named BIG-registered physician — with their title, function, and BIG registration number. This applies to foreign clinics too: a “comparable foreign register” (e.g. Belgium’s RIZIV) is accepted in place of BIG, but the traceability requirement cannot be omitted. A beauty salon that advertises injectables without demonstrating lawful BIG professional cover can face an ALERT ruling — confirmed in the 2024 Sensual Aestetics case, where the RCC treated the ad as a threat to public health.
In practice: Injectable treatment ads with no physician name or registration, salon websites advertising filler/Botox services without naming a supervising BIG-registered doctor.
The risk: Guaranteeing treatment outcomes (“gegarandeerd resultaat,” “gegarandeerd pijnloos”) and claiming that procedures are risk-free (“risicovri,” “zonder risico’s”) are prohibited under Wmg Art. 39, civil consumer law, and the Dutch Advertising Code. These claims are also inconsistent with what Dutch law requires clinics to tell patients before treatment — which includes discussing risks, alternatives, and realistic outcomes.
In practice: “Garantie op uw resultaat,” “100% veilig,” “schone huid gegarandeerd,” “pijnloze behandeling altijd.”
The risk: Using before/after photos in marketing requires written, GDPR-compliant consent specifically for marketing publication. Consent to treatment is not consent to marketing. Health-related imagery constitutes special-category personal data under GDPR. The Dutch Data Protection Authority (AP) requires that this consent be specific, documented, and revocable. In a medical cosmetic context, the CCBA separately requires written permission for use of treated-person imagery. Treatment intake forms do not cover this.
In practice: Before/after galleries on clinic websites, before/after Instagram posts, influencer stories showing treatment results — all require separate, documented marketing consent for each identifiable person shown.
The Grey Areas — Allowed Under Specific Conditions
Not outright banned — but how you handle these determines whether you are within the rules or exposed to a complaint.
Allowed if: Tariff information is transparent, factual, and not the dominant message. Price is presented alongside substantive information about the treatment (what it involves, risks, expected outcomes, suitability criteria). Wmg Art. 38 actually requires tariff transparency — pricing information on your website is necessary, not optional.
Crosses the line if: Price becomes the headline and primary selling point, with clinical information relegated to small print or absent entirely. Package deals and volume discounts that make the commercial offer look more like a consumer promotion than a medical service.
Allowed if: The commercial relationship between clinic and publisher/influencer is clearly disclosed (at the start of the content, not in a footnote). The story is truthful, does not omit material information, and does not use selective positive-result editing. Patient stories are not automatically banned — the test is recognition and accuracy.
Crosses the line if: The commercial relationship is not disclosed or is buried. The story selectively presents positive outcomes without reflecting the realistic range of results. Advertorial content is designed to look editorial. Any medical cosmetic context where the testimonial functions as a recommendation or endorsement.
Allowed if: #Advertentie or #Reclame appears at the start of the post. No prescription medicine brand names used. No before/after imagery. No discount codes or promotional mechanics. Mandatory CCBA warning text included if the treatment is a physician-performed medical cosmetic procedure. The influencer’s content stays within the same objectivity and non-intrusiveness standards required of the clinic itself.
Crosses the line if: Any of the above conditions are missing. The clinic is co-responsible for what its contracted influencer publishes — the IGJ has confirmed that third parties who place unlawful promotional content bear responsibility.
Allowed if: The page clearly and actively states whether the clinic has a contract with the patient’s health insurer — or does not. Since 1 September 2024, the NZa transparency regulation requires this disclosure to be active and demonstrable, not just available on request.
Crosses the line if: The page omits this information entirely, or buries it in general terms and conditions. For private clinics without insurer contracts, this omission is a material failure under Wmg Art. 39 and creates unfair commercial practices exposure.
Allowed if: The mark is real, current, and verifiable. The source is named. It is not used to imply competitive superiority or to suggest official government approval where none exists.
Crosses the line if: The mark is not currently held, is from a body the clinic is not actually affiliated with, or implies an official approval or certification that does not exist. Dutch civil law explicitly blacklists using trust or quality labels without authorization — this is a hard violation, not a grey area, once the label is fake or expired.
Allowed if: A clinic markets aesthetic treatments using healthcare-appropriate language, demonstrates BIG-registered professional cover for any injectable procedures, and stays within the medical cosmetic advertising code.
Crosses the line if: A business frames injectable procedures as beauty or wellness services to avoid healthcare advertising rules. Once a Dutch advertising body sees injectable procedure advertising — regardless of how the business categorizes itself — it applies Wet BIG reserved-acts analysis and public-health risk assessment. The 2024 Sensual Aestetics ruling made this unambiguously clear: beauty framing does not protect injectable advertising from healthcare law.
The Cross-Border Trap for CEE Clinics
⚠ If your clinic is outside the Netherlands and targeting Dutch patients — read this
Dutch consumer law (BW) applies when your advertising targets Dutch consumers — regardless of where your clinic is located. If your ads are in Dutch, your pricing pages are in euros, or your social campaigns are geo-targeted to the Netherlands, Dutch unfair commercial practices rules apply to you. There is no requirement to have a Dutch representative (unlike Germany’s HWG § 13), but that does not mean you are exempt from Dutch law.
The CCBA’s mandatory BIG traceability requirement also catches foreign clinics directly: you must name a treating physician with a BIG registration number — or a comparable foreign register (Belgium’s RIZIV is explicitly accepted). You cannot omit this requirement because treatment happens abroad. The mandatory safety warning text must also appear in your Dutch-language ads. These two requirements — physician traceability and the warning text — are the most common failures for CEE clinics running Dutch campaigns.
The Legal Framework — For Reference
For those who want the statutory and regulatory detail behind the practical rules above.
| Law / Code | What it covers | Enforcing authority | Max penalty |
|---|---|---|---|
| Wmg Art. 38–39 (Healthcare Market Regulation Act) | Tariff transparency; prohibition on misleading provider information including advertising | NZa (Netherlands Authority for Health Care Markets) | Administrative fine (exact ceiling unverified — marked as open item) |
| BW Art. 6:193b–193g (Dutch Civil Code — Unfair Commercial Practices) | Prohibition on misleading acts, misleading omissions, blacklisted practices (fake quality marks, false endorsements) | ACM (Authority for Consumers and Markets) | Administrative fine; consumer right to void contract and claim damages |
| WGBO Art. 7:448–7:450 (Medical Treatment Contract Act) | Pre-treatment information obligations: clinicians must inform patients about nature, risks, alternatives and costs before consent. Marketing that overpromises creates dual liability here. | Disciplinary bodies; civil courts | Contract annulment; damages; disciplinary sanction |
| Wet BIG Art. 47 (Individual Healthcare Professions Act) | Professional discipline for BIG-registered practitioners — marketing conduct inconsistent with proper professional practice is in scope | Tuchtcolleges (Disciplinary tribunals) | Reprimand, conditional suspension, fine, erasure from BIG register |
| NRC / CCBA (Dutch Advertising Code + Code for Medical Cosmetic Treatments by Physicians) | Self-regulatory code for physician-performed medical cosmetic advertising: mandatory warning text, BIG traceability, no time pressure, no price-first, written consent for imagery | RCC (Advertising Code Committee) + College of Appeal | Ruling with recommendation to cease; ALERT = public dissemination of ruling |
| RSM (Social Media and Influencer Code) | Disclosure of commercial relationships in social media; prohibition on misleading editing; applies to clinics and their contracted influencers | RCC | Ruling with recommendation; ALERT for serious violations |
| CPG (Code for Public Medicine Advertising) | Prohibition on public advertising for prescription-only medicines; applies to clinics, influencers, and third-party publishers | IGJ (Healthcare and Youth Inspectorate); RCC | IGJ administrative fine (published publicly from 2026); criminal referral for serious/repeated violations |
| GDPR / AP (General Data Protection Regulation) | Health data is special-category personal data; before/after imagery, patient testimonials, and health-interest CRM targeting require explicit, documented, and revocable consent for marketing use | AP (Dutch Data Protection Authority) | Administrative fine up to 4% annual turnover or €20 million (GDPR maximum) |
Key enforcement cases
RCC 2019/00470 — M1 Med Beauty (August 2019): An Instagram ad offering “20% korting op alle injectables” with a one-month validity period for Botox and filler treatments at a new clinic was ruled to violate CCBA Art. 2. The limited validity period created unlawful time pressure for a non-medically-necessary treatment. The ad was withdrawn before the formal ruling was issued, but the legal point was confirmed: time-limited offers on medical cosmetic treatments are inherently unlawful under the Dutch code, regardless of how reasonable the discount might appear commercially.
RCC 2024/00313 — Sensual Aestetics (August 2024): A beauty salon’s Facebook and website advertising for filler, Botox, and injectable procedures was found to constitute a threat to physical public health under NRC Art. 4 because the salon could not demonstrate lawful BIG-registered professional cover for injectable reserved acts. The ruling was issued as an ALERT — publicly disseminated across Dutch advertising industry channels. This case defines the beauty-to-healthcare escalation risk: once you advertise injectables, Dutch bodies apply Wet BIG and public health analysis, not beauty advertising rules.
RCC 2025/00608 — Fairday Clinics (January 2026): A Botox “stackelkorting” (stacking discount) Instagram ad was ruled to violate CCBA Art. 2, even though Fairday argued the pricing was permanent (not a temporary campaign). The RCC held that the ad focused entirely on price, lacked any meaningful information about the nature, operation or risks of the treatment, and used price as the sole sales argument. This ruling extends the Dutch price-promotion prohibition to permanent package pricing — not just countdown discounts.
Legal disclaimer: This page provides general information about Dutch medical advertising regulations for educational purposes only and does not constitute legal advice. Regulations change. Verify all compliance requirements with a qualified legal professional in the relevant jurisdiction before publishing any marketing materials. MedicalServiceFinder.com accepts no liability for decisions made based on this content.
Last updated: June 2026 | Primary sources: Wmg (wetten.overheid.nl/BWBR0020078), NRC/CCBA (reclamecode.nl), IGJ (igj.nl/zorgsectoren/geneesmiddelen/geneesmiddelenreclame), NZa (nza.nl), ACM (acm.nl), AP (autoriteitpersoonsgegevens.nl)
